Get started
Author

Meghanne Lomibao

Observed name: M. Lomibao
ORCID: 0009-0007-2544-8599
Observed ORCID: 0009-0007-2544-8599
OpenAlex ID: A5117723173
Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study
2025 · Sarah Waliany, Shambo Guha Roy, et al. · Journal of the National Comprehensive Cancer Network · 2
PDF
Second- and third-line outcomes after selective RET inhibitor failure in RET fusion-positive metastatic lung cancer: A real-world analysis from the RET-MAP registry
2026 · Daniela Miliziano, Julia K. Rotow, et al. · Clinical Cancer Research
Type II ROS1 Inhibition Overcomes Type I Inhibitor Resistance in ROS1 Fusion–Positive Lung Cancers: A Phase II Trial of Cabozantinib
2026 · Jaime Rubio-Perez, Matteo Repetto, et al. · Clinical Cancer Research
Data from Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry
2026 · Arianna Marinello, Julia K. Rotow, et al.
Supplementary Data1 from Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry
2026 · Arianna Marinello, Julia K. Rotow, et al.
PP01.06: Clinico-Genomic Characteristics and Treatment Outcomes of Patients with Advanced ALK-Rearranged Squamous and Adenosquamous Non-Small Cell Lung Cancers
2026 · Emily A. Miao, Beow Yeap, et al. · Journal of Thoracic Oncology
PP01.07: Activity of Bevacizumab Combined With Chemotherapy in Advanced RET-Rearranged Non-Small Cell Lung Cancer
2026 · Mihaela Aldea, Daniela Esposito, et al. · Journal of Thoracic Oncology
First-Line Chemoimmunotherapy and Chemotherapy Outcomes in Patients With RET Fusion-Positive Lung Cancer in LIBRETTO-431
2026 · Can Cui, Sabrina Lin, et al. · Journal of Thoracic Oncology
Impact of KRAS co-mutations on the efficacy of durvalumab in patients with locally advanced non–small cell lung cancer (LA-NSCLC) treated with concurrent chemoradiotherapy (ChRT).
2026 · Jaime Rubio Perez, Ling Feng Ye, et al. · Journal of Clinical Oncology
Retreatment with First-Generation Selective RET Inhibitors in RET -Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry
2026 · Arianna Marinello, Julia K. Rotow, et al. · Clinical Cancer Research
Abstract 2434: Prognostic and predictive effects of TP53 co-mutations and RET fusion partners in RET -rearranged advanced NSCLC
2026 · Daniela Miliziano, Julia K. Rotow, et al. · Cancer Research
Clinicogenomic Characteristics and Treatment Outcomes of Patients With Advanced ALK -Rearranged Squamous and Adenosquamous Non–Small Cell Lung Cancers
2026 · Emily A. Miao, Beow Yeap, et al. · JCO Precision Oncology
P3.03.32 Multi-Omic Characterization of ALK Fusion LUADs Reveals Overactivation of DNA Replication as a Contributor to ALK TKI Resistance
2025 · E. Redin, Y. Zhang, et al. · Journal of Thoracic Oncology
2009P Real world data on fusion-positive advanced lung cancers treated with the combination of chemotherapy and tyrosine kinase inhibition
2025 · S. Daher, J. Rubio Perez, et al. · Annals of Oncology
Rechallenge with first-generation RET inhibitors in RET -rearranged NSCLC pre-treated with selpercatinib or pralsetinib: Results from the RET MAP registry.
2025 · Arianna Marinello, Julia K. Rotow, et al. · Journal of Clinical Oncology
PDF
Works count: 15
Citation count: 2
H-index: 1
I10-index:
Year
Topic
Type